Entact Bio adds **John G. Houston, Ph.D.**, a biopharma executive with experience in developing the first **FDA-approved PROTAC drug**, to its board. His appointment aims to bolster the company’s focus on **induced-proximity technologies** in drug discovery. Houston’s expertise in **PROTACs (Proteolysis Targeting Chimeras)** aligns with Entact’s mission to advance precision protein degradation therapies.
Entact Bio names Ruben Tommasi, Ph.D., as Chief Scientific Officer. Tommasi brings over three decades of experience in pharmaceutical and biotech R&D to lead the development of Entact’s targeted protein enhancement platform. The company focuses on precision medicines designed to enhance beneficial protein function for patient benefit.
Entact Bio names Michael Gutch, Ph.D., as its new Chief Operating Officer. The appointment expands leadership for the biotechnology company’s operational strategy. Gutch brings expertise in scaling life sciences ventures.
Victoria Richon is launching Entact Bio, a company developing protein-enhancing drugs to address multiple diseases. The venture emerges from stealth mode to explore therapeutic approaches targeting protein function. Entact Bio aims to leverage innovations in this growing field of biopharmaceuticals.
